Drug updated on 9/5/2024
Dosage Form | Capsule (oral; 40 mg, 60 mg, 80 mg) |
Drug Class | Vesicular monoamine transporter 2 inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adults with tardive dyskinesia.
- For the treatment of chorea associated with Huntington’s disease.
Latest News
Summary
- Ingrezza (valbenazine) is indicated for the treatment of adults with tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.
- This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
- VMAT-2 inhibitors, including valbenazine, were more effective than placebo in achieving slight improvement in psychosis (RR = 1.77, 95% CI 1.03, 3.04), and were as effective as active comparators (RR = 1.05, 95% CI 0.6, 1.81).
- Valbenazine and deutetrabenazine both showed significant reductions in TD symptoms, with a ≥50% reduction in AIMS scores; valbenazine at 80 mg/day demonstrated robust results in both short-term and long-term studies, and deutetrabenazine was similarly effective at 12 mg twice daily.
- A specific trial in the Asian population confirmed significant improvements in AIMS scores for both valbenazine and deutetrabenazine, validating their effectiveness in this subgroup.
- Valbenazine and deutetrabenazine demonstrated favorable safety profiles with low rates of serious adverse events, without significant increases in QT prolongation, parkinsonism, suicidal ideation, or mortality observed.
- There is limited long-term safety data available for deutetrabenazine.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Ingrezza (valbenazine) Prescribing Information. | 2023 | Neurocrine Biosciences, Inc., San Diego, CA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis. | 2024 | Psychopharmacology |
Comparative analysis of deutetrabenazine and valbenazine as VMAT2 inhibitors for tardive dyskinesia: a systematic review. | 2024 | Tremor and Other Hyperkinetic Movements |
Treatment recommendations for tardive dyskinesia. | 2019 | Canadian Journal of Psychiatry |
A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. | 2019 | Therapeutic Advances in Psychopharmacology |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia third edition. | 2021 | American Psychiatric Association |